Autoimmune Encephalitis Associated Antibodies - Pilot EQA
| Accreditation Status: | Currently not accredited to ISO 17043 | ||||||||
| Date Scheme started: | 2023 | ||||||||
| Clinical Applicability: | Autoimmune encephalitis with no known common infectious cause | ||||||||
| Analytes: | NMDAR, CASPR2, AMPA-1, AMPA-2, LGI1, DPPX, GABA-B, MOG, AQP4, GAD65 (SER/062) | ||||||||
| Units for Reporting: | Qualitative: Positive / Negative | ||||||||
| Samples Distributed: | Liquid format. Normal and pathological human serum | ||||||||
| Number of Distributions per year: | 6 | ||||||||
| Number of Samples per Distribution: | 2 | ||||||||
| Frequency of Distributions: | Every two months as outlined in the Distribution Schedule | ||||||||
| Schedule of Analysis: | Data entry is via the web for the submission of results. Data analysis commences 21 days after sample dispatch. Late returns are accepted and will contribute to the laboratory's cumulative performance statistics. | ||||||||
| Data Analysis: | Qualitative responses are assessed in relation to the designated response | ||||||||
| Performance Scoring: | MI Scoring | ||||||||
| Criteria of Performance: |
Laboratory performance is classified in terms of OMIS over a running analytical window of 6 distributions (12 months) The categories of performance are:
|
||||||||
| Persistent Poor Performance: |
Defined as being in the Poor Performance category for two or more successive Distributions |